DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Schmid P, Abraham J, Chan S. et al.
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
J Clin Oncol 2018;
36 (Suppl.) Abstr.. 1007
We do not assume any responsibility for the contents of the web pages of other providers.